Royal Bank of Canada Has $109,000 Stake in MiMedx Group, Inc $MDXG

Royal Bank of Canada trimmed its holdings in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 87.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,468 shares of the company’s stock after selling 186,366 shares during the period. Royal Bank of Canada’s holdings in MiMedx Group were worth $109,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in shares of MiMedx Group by 22.4% during the 1st quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company’s stock valued at $11,928,000 after acquiring an additional 552,806 shares during the last quarter. Hillsdale Investment Management Inc. bought a new position in shares of MiMedx Group in the 4th quarter worth $7,134,000. Dimensional Fund Advisors LP grew its stake in shares of MiMedx Group by 8.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,694,002 shares of the company’s stock worth $10,640,000 after purchasing an additional 214,633 shares during the period. Vanguard Group Inc. grew its stake in shares of MiMedx Group by 5.6% during the fourth quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock worth $48,637,000 after purchasing an additional 382,623 shares during the period. Finally, Paradigm Capital Management Inc. NY grew its stake in shares of MiMedx Group by 39.1% during the first quarter. Paradigm Capital Management Inc. NY now owns 3,410,300 shares of the company’s stock worth $13,471,000 after purchasing an additional 959,100 shares during the period. 79.15% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on MDXG. Raymond James Financial set a $8.00 target price on MiMedx Group in a research note on Monday, August 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price target on shares of MiMedx Group in a research note on Monday, August 17th. Wall Street Zen upgraded shares of MiMedx Group from a “sell” rating to a “hold” rating in a research report on Saturday. Seaport Research Partners downgraded shares of MiMedx Group to a “neutral” rating in a research report on Monday, August 17th. Finally, Craig Hallum lifted their price objective on shares of MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, MiMedx Group presently has an average rating of “Moderate Buy” and a consensus target price of $8.57.

MiMedx Group Stock Up 0.9%

MiMedx Group stock opened at $4.54 on Tuesday. The stock has a market capitalization of $661.75 million, a PE ratio of 113.53 and a beta of 1.45. MiMedx Group, Inc has a twelve month low of $3.03 and a twelve month high of $7.97. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average of $4.20 and a 200-day moving average of $4.08.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The business had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. On average, equities research analysts anticipate that MiMedx Group, Inc will post -0.1 EPS for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.